Enlivex Ltd.
DE ˙ DB
0,72 € ↑0,04 (5,84%)
2026-06-02
DEL PRIS
SecurityDE:1BT / Enlivex Ltd.
InstitutionRenaissance Technologies Llc
ManagerJames Simons
Latest Disclosed Ownership128,192 shares
Latest Disclosed Value $ 119,231
Renaissance Technologies Llc reports 59.13% decrease in ownership of 1BT / Enlivex Ltd.

On May 14, 2026 - Renaissance Technologies Llc filed a 13F-HR form disclosing ownership of 128,192 shares of Enlivex Ltd. (DE:1BT) valued at $99,990 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 313,628 shares of Enlivex Ltd.. This represents a change in shares of -59.13% during the quarter. The current value of the position is $92,939 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F ENLIVEX COM M4130Y106 128,192 -185,436 -59.13 119 -45.91 0.0002
2026-02-12 2025-12-31 13F ENLIVEX THERAPEUTICS COM M4130Y106 313,628 156,336 99.39 221 34.97 0.0003
2025-11-13 2025-09-30 13F ENLIVEX THERAPEUTICS COM M4130Y106 157,292 -11,100 -6.59 164 -13.30 0.0002
2025-08-13 2025-06-30 13F ENLIVEX THERAPEUTICS COM M4130Y106 168,392 -12,897 -7.11 189 7.43 0.0003
2025-05-14 2025-03-31 13F ENLIVEX THERAPEUTICS COM M4130Y106 181,289 22,297 14.02 176 -5.91 0.0003
2025-02-13 2024-12-31 13F ENLIVEX THERAPEUTICS COM M4130Y106 158,992 84,203 112.59 186 48.80 0.0003
2024-11-13 2024-09-30 13F ENLIVEX THERAPEUTICS COM M4130Y106 74,789 3,100 4.32 126 23.76 0.0002
2024-08-09 2024-06-30 13F ENLIVEX THERAPEUTICS COM M4130Y106 71,689 1,800 2.58 102 0.0002
2024-05-13 2024-03-31 13F ENLIVEX THERAPEUTICS COM M4130Y106 69,889 7,800 12.56 0 0.0004
2024-02-13 2023-12-31 13F ENLIVEX THERAPEUTICS COM M4130Y106 62,089 3,200 5.43 0 0.0003
2023-11-14 2023-09-30 13F ENLIVEX THERAPEUTICS COM M4130Y106 58,889 2,200 3.88 0 0.0002
2023-08-11 2023-06-30 13F ENLIVEX THERAPEUTICS COM M4130Y106 56,689 2,000 3.66 0 0.0002
2023-05-12 2023-03-31 13F ENLIVEX THERAPEUTICS COM M4130Y106 54,689 500 0.92 0 0.0003
2023-02-13 2022-12-31 13F ENLIVEX THERAPEUTICS COM M4130Y106 54,189 -4,700 -7.98 0 -100.00 0.0003
2022-11-14 2022-09-30 13F ENLIVEX THERAPEUTICS COM M4130Y106 58,889 -5,300 -8.26 250 -13.79 0.0004
2022-08-12 2022-06-30 13F ENLIVEX THERAPEUTICS COM M4130Y106 64,189 500 0.79 290 -18.54 0.0003
2022-05-13 2022-03-31 13F ENLIVEX THERAPEUTICS COM M4130Y106 63,689 -4,000 -5.91 356 -15.84 0.0004
2022-02-11 2021-12-31 13F ENLIVEX THERAPEUTICS COM M4130Y106 67,689 -20,300 -23.07 423 -51.32 0.0005
2021-11-12 2021-09-30 13F ENLIVEX THERAPEUTICS COM M4130Y106 87,989 -107,717 -55.04 869 -50.11 0.0011
2021-08-13 2021-06-30 13F ENLIVEX THERAPEUTICS COM M4130Y106 195,706 -94,700 -32.61 1,742 -45.92 0.0022
2021-05-13 2021-03-31 13F ENLIVEX THERAPEUTICS COM M4130Y106 290,406 11,300 4.05 3,221 36.89 0.0040
2021-02-10 2020-12-31 13F ENLIVEX THERAPEUTICS COM M4130Y106 279,106 -19,400 -6.50 2,353 32.71 0.0026
2020-11-13 2020-09-30 13F ENLIVEX THERAPEUTICS COM M4130Y106 298,506 26,800 9.86 1,773 28.95 0.0018
2020-08-13 2020-06-30 13F ENLIVEX THERAPEUTICS COM M4130Y106 271,706 176,716 186.04 1,375 208.99 0.0012
2020-05-14 2020-03-31 13F ENLIVEX THERAPEUTICS COM M4130Y106 94,990 56,600 147.43 445 38.20 0.0004
2020-02-13 2019-12-31 13F ENLIVEX THERAPEUTICS COM M4130Y106 38,390 14,600 61.37 322 -49.29 0.0002
2019-11-13 2019-09-30 13F ENLIVEX THERAPEUTICS COM M4130Y106 23,790 3,900 19.61 635 48.36 0.0005
2019-08-12 2019-06-30 13F ENLIVEX THERAPEUTICS COM M4130Y106 19,890 2,201 12.44 428 95.43 0.0004
2019-05-14 2019-03-31 13F ENLIVEX THERAPEUTICS COM M4130Y106 17,689 -112,439 -86.41 219 116.83 0.0002
2019-02-12 2018-12-31 13F BIOBLAST PHARMA SHS NEW M20156119 130,128 13,500 11.58 101 -35.67 0.0001
2018-11-13 2018-09-30 13F BIOBLAST PHARMA SHS NEW M20156119 116,628 15,868 15.75 157 -4.85 0.0002
2018-08-13 2018-06-30 13F/A-1 BIOBLAST PHARMA SHS NEW M20156119 100,760 4,100 4.24 165 -13.61 0.0002
2018-08-13 2018-06-30 13F BIOBLAST PHARMA SHS NEW M20156119 96,660 191
2018-05-14 2018-03-31 13F BIOBLAST PHARMA SHS NEW M20156119 96,660 18,600 23.83 191 7.30 0.0002
2018-02-13 2017-12-31 13F BIOBLAST PHARMA SHS NEW M20156119 78,060 28,900 58.79 178 67.92 0.0002
2017-11-13 2017-09-30 13F BIOBLAST PHARMA SHS NEW M20156119 49,160 -158,540 -76.33 106 -23.74 0.0001
2017-08-11 2017-06-30 13F BIOBLAST PHARMA SHS M20156101 207,700 48,400 30.38 139 14.88 0.0002
2017-05-12 2017-03-31 13F BIOBLAST PHARMA SHS M20156101 159,300 40,400 33.98 121 -2.42 0.0002
2017-02-13 2016-12-31 13F BIOBLAST PHARMA SHS M20156101 118,900 34,600 41.04 124 -15.07 0.0002
2016-11-14 2016-09-30 13F BIOBLAST PHARMA SHS M20156101 84,300 60,200 249.79 146 274.36 0.0003
2016-08-12 2016-06-30 13F BIO BLAST PHARMA SHS M20156101 24,100 24,100 39 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.